Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CytomX Therapeutics: Q2 Earnings Snapshot AP - Thu Aug 6, 4:04PM CDT

CytomX Therapeutics: Q2 Earnings Snapshot

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update GlobeNewswire - Thu Aug 6, 3:15PM CDT

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal cancer (CRC) expected by the end of 2026. Registrational study planned for initiation in 1H 2027...

CTMX : 3.37 (+0.60%)
CytomX Reports Tomorrow With Analysts Already Looking Past August Barchart - Wed Aug 5, 4:08PM CDT

Barchart Research What to Expect from CTMX Earnings CTMX Generated August 5, 2026 Current Price $3.35 EPS Estimate $$-0.11 Consensus Rating Strong Buy Average Move 25.62% CytomX Reports Tomorrow With Analysts...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer GlobeNewswire - Mon Aug 3, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 GlobeNewswire - Thu Jul 30, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors GlobeNewswire - Mon Jul 27, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer GlobeNewswire - Wed Jun 3, 7:00AM CDT

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX’s PROBODY ® and Regeneron's Veloci-Bi ® platforms - - CytomX...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics to Present at Upcoming June Investor Conferences GlobeNewswire - Thu May 21, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management...

CTMX : 3.37 (+0.60%)
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs GlobeNewswire - Mon May 18, 7:00AM CDT

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment...

CTMX : 3.37 (+0.60%)
MarketBeat.com
CytomX Therapeutics Q1 Earnings Call Highlights MarketBeat - Thu May 7, 7:38PM CDT

CytomX Therapeutics (NASDAQ:CTMX) executives highlighted progress across the company’s lead clinical programs and reviewed first-quarter 2026 financial results, emphasizing continued development momentum...

CTMX : 3.37 (+0.60%)

Barchart Exclusives

The Data Center Boom Is Powering Utility Earnings. Here Is My Favorite Way to Play the Trend. Barchart - Thu Aug 6, 6:30PM CDT
Utility companies are increasingly benefiting from the AI data center boom, and here is my favorite way to gain exposure to this investment theme. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.